STAAR Surgical Company

Valuation Analysis

About the Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as we

STAAR Surgical Company Stock at a Glance

STAAR Surgical Company (STAA) is currently trading at $28.37 with a market capitalization of $1.4B. The 52-week range spans from $15.59 to $35.87; the current price is 20.9% below the yearly high. Year-over-year revenue growth stands at +119.6%.

💰 Dividend

STAAR Surgical Company currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

9 analysts rate STAAR Surgical Company (STAA) on consensus: None. The average price target is $29.67, implying +4.57% from the current price. Analyst price targets range from $23.00 to $40.00.

STAAR Surgical Company: The Investment Case in Detail

STAAR Surgical Company (STAA) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 119.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 76.89%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 22.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.76, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 88.62x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (22.1%).

Trading Data

Related Stocks in the Same Sector

Where can I buy STAAR Surgical Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.